Jacobs syndrome clinical trials
The registry lists 27 studies for Jacobs syndrome across more than 10 countries. 2 are recruiting or about to start. 1 of them are mainly about Jacobs syndrome (how this is decided). Per ClinicalTrials.gov, last updated 2026-08-31.
Get an email when these change. Save the Jacobs syndrome studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
GlaxoSmithKline (9) · Amgen (2) · Novartis Pharmaceuticals (2) · M.D. Anderson Cancer Center (2) · PrECOG, LLC. (1) · St. Jude Children's Research Hospital (1) · University Hospital, Bordeaux (1) · Weill Medical College of Cornell University (1)
What is being tested here
Drugs under test in Jacobs syndrome studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Eltrombopag | 0 | 7 | 13 |
| Romiplostim | 0 | 2 | 3 |
| Recombinant human thrombopoietin | 0 | 0 | 2 |
| Avatrombopag | 0 | 0 | 1 |
| Carboplatin | 0 | 0 | 1 |
| Cytarabine | 0 | 0 | 1 |
Who these studies take
Of the 1 Jacobs syndrome studies recruiting now, 1 (100%) set no upper age limit and 0 (0%) stop at 75 or younger. 0 (0%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 0 (0%) | 0 (0%) |
| 18 | 1 (100%) | 1 (100%) |
| 30 | 1 (100%) | 1 (100%) |
| 40 | 1 (100%) | 1 (100%) |
| 50 | 1 (100%) | 1 (100%) |
| 65 | 1 (100%) | 1 (100%) |
| 75 | 1 (100%) | 1 (100%) |
| 85 | 1 (100%) | 1 (100%) |
Across all 27 studies, recruiting or not: 22% stop at 75 or younger and 15% at 65; 22% take children; 4% are for women only and 0% for men only; 4% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
Studies
Recruiting first, then most recently updated. Showing 27 of 27. search them.
- Contribution of Anti-platelet Antibodies Identified With MAIPA Assay in the Demonstration of the Auto-immune Character of a Thrombocytopenia at DiagnosisRecruitingNCT04800458Not applicable1 country
- The Predictive Value of Lubricin in Patients With Infective EndocarditisEnrolling by invitationNCT062667411 country
- Avatrombopag vs. Placebo for CIT in GI MalignanciesCompletedNCT05772546Phase 21 country
- Safety and Efficacy of 2 Concentrations of Lubricin vs Sodium Hyaluronate in Ocular Discomfort After Refractive Surgery.CompletedNCT03031327Not applicable1 country
- A Phase 2 Study to Evaluate the Efficacy and Safety of AMG531 in Aplastic AnemiaCompletedNCT02094417Phase 21 country
- Phase II Eltrombopag in Chronic Lymphocytic Leukemia (CLL)CompletedNCT01168921Phase 21 country
- An Open Label Study of Romiplostim in Adult Thrombocytopenic Subjects With ITPCompletedNCT00508820Phase 3
- Romiplostim (AMG 531) Versus Medical Standard of Care for Immune (Idiopathic) Thrombocytopenic PurpuraCompletedNCT00415532Phase 3
- Eltrombopag vs. rhTPO to Increase Platelet Level After HSCTCompletedNCT03515096Phase 31 country
- Trial of Eltrombopag During Consolidation Therapy in Adults With AML in Complete RemissionTerminatedNCT01656252Phase 1/21 country
- A Study to Assess the Safety and Efficacy of Eltrombopag in Japanese Subjects With Refractory, Moderate or More Severe Aplastic AnemiaCompletedNCT02148133Phase 21 country
- rhTPO Mobilized Auto Cryo Platelets For GYN Patients Receiving CarboplatinCompletedNCT00038012Not applicable1 country
- Eltrombopag To Reduce The Need For Platelet Transfusion In Subjects With Chronic Liver Disease And Thrombocytopenia Undergoing Elective Invasive ProceduresTerminatedNCT00678587Phase 313 countries
- A Study of Eltrombopag or Placebo in Combination With Azacitidine in Subjects With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-risk Myelodysplastic Syndromes (MDS)TerminatedNCT02158936Phase 330 countries
- Eltrombopag Treatment of Thrombocytopenia in Subjects With Advanced Myelodysplastic Syndrome (MDS) or Secondary Acute Myeloid Leukemia After MDS (sAML/MDS)CompletedNCT00903422Phase 111 countries
- SB-497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adult Cancer Patients Receiving ChemotherapyCompletedNCT00102726Phase 219 countries
- Comparing Intermediate-dose CTX+ G-CSF Plus or Not rhTPO for PB CD34+ Cells Mobilization in MM PatientsStatus unknownNCT02572596Not applicable1 country
- A Retrospective Chart Review of Thirty Three Children Who Have Received Clinical Treatment With Either Romiplostim or Eltrombopag From 2009-2013CompletedNCT019742321 country
- Effectiveness of a Simplified Short Regimen for Multidrug Resistant Tuberculosis in UzbekistanStatus unknownNCT024965721 country
- Clinical Trial for Non-responders Who Previously Participated in Eltrombopag Studies TPL 103922 or TPL 108390CompletedNCT00996216Phase 39 countries
- Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Subjects With Hepatitis C Related Liver DiseaseCompletedNCT00516321Phase 325 countries
- Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Benefit Subjects With Hepatitis C Liver DiseaseCompletedNCT00529568Phase 323 countries
- SB-497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adults With Refractory Immune Thrombocytopenic Purpura (ITP)CompletedNCT00102739Phase 213 countries
- SB497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adults With Thrombocytopenia Due To Hepatitis CCompletedNCT00110799Phase 25 countries
- Clinical Evaluation of SB-497115-GR in Chronic Idiopathic Thrombocytopenic Purpura (ITP)CompletedNCT00540423Phase 31 country
- Recombinant Human Thrombopoietin in Children Receiving Ifosfamide, Carboplatin, and Etoposide ChemotherapyCompletedNCT00187109Phase 1/21 country
- Thrombopoietin Levels and Platelet Transfusion in NeonatesCompletedNCT005494841 country